Schering-Plough announced FDA approval on a key pipeline antipsychotic today, and is building a US sales force for the Q4 launch. The product, Saphris (asenapine), received approval on two indications ...

Please provide your email address to receive an email when new articles are posted on . Results from a randomized trial indicate Saphris was effective and well-tolerated among adolescents with bipolar ...

allergan The labeling for Saphris (asenapine; Allergan) sublingual tablets has been updated with an expanded bipolar I disorder indication, dosage modifications, and a new contraindication. The ...

Saphris Actavis announced that the Food and Drug Administration (FDA) has approved Saphris (asenapine) as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I ...

Pharmaceutical company Forest Laboratories (FRX) announced plans on Monday to streamline operations in a bid to save money, while also saying that it is aiming to bolster sales by buying the U.S.

Positive news flowed in at Actavis plc ACT with the FDA approving its supplemental new drug application for Saphris as a monotherapy for acute manic or mixed episodes associated with bipolar I ...

WASHINGTON, Aug. 14 (UPI) -- Schering-Plough Corp.'s asenapine has been cleared for sale as a treatment for schizophrenia and bipolar disorder in adults, U.S. authorities said. The drug is to be made ...

Schering-Plough fielded questions from the U.S. Food and Drug Administation in stride, as it prepares a response to inquiries about its schizophrenia treatment. The government oversight agency sent a ...

(MENAFN- IMARC Group) IMARC Group's report, titled “Asenapine (Saphris) Manufacturing Plant Project Report 2024: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost ...